Viridian Therapeutics, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Viridian Therapeutics, Inc./DE (VRDN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 770.84 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-12-31 was -127.00K shares, a 573.30% decline year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-09-30 was 41.90K shares, a 2693.07% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-06-30 was 30.12K shares, a 569.40% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-03-31 was 65.41K shares, a 6440.70% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 770.84K shares.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2016 was 10.43K shares, a 69.19% decline from fiscal 2015.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2015 was 33.83K shares, a 1253.32% increase from fiscal 2014.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2014 was 2.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 770.84K shares 10-K · filed 2026-02-26 | |||
| 2016-12-31 | -127.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | -85.11K shares derived: sum of 2 quarters · filed 2017-03-24 | -54.98K shares derived: sum of 3 quarters · filed 2017-03-24 | 10.43K shares 10-K · filed 2017-03-24 |
| 2016-09-30 | 41.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | 72.02K shares derived: sum of 2 quarters · filed 2016-10-26 | 137.43K shares 10-Q · filed 2016-10-26 | 164.26K shares derived: sum of 4 quarters · filed 2016-10-26 |
| 2016-06-30 | 30.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 95.53K shares 10-Q · filed 2016-08-15 | 122.36K shares derived: sum of 3 quarters · filed 2016-08-15 | 123.86K shares derived: sum of 4 quarters · filed 2016-08-15 |
| 2016-03-31 | 65.41K shares 10-Q · filed 2016-05-16 | 92.24K shares derived: sum of 2 quarters · filed 2016-05-16 | 93.74K shares derived: sum of 3 quarters · filed 2016-05-16 | 98.24K shares derived: sum of 4 quarters · filed 2016-05-16 |
| 2015-12-31 | 26.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | 28.33K shares derived: sum of 2 quarters · filed 2016-03-21 | 32.83K shares derived: sum of 3 quarters · filed 2016-03-21 | 33.83K shares 10-K · filed 2016-03-21 |
| 2015-09-30 | 1.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | 6.00K shares derived: sum of 2 quarters · filed 2015-11-13 | 7.00K shares 10-Q · filed 2015-11-13 | |
| 2015-06-30 | 4.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | 5.50K shares 10-Q · filed 2015-08-14 | ||
| 2015-03-31 | 1.00K shares 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | 2.50K shares 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |